Home > Biochemistry News > Biotechnology News > Bayer's ErSO therapy for metastatic breast cancer has not yet entered clinical trials

Bayer's ErSO therapy for metastatic breast cancer has not yet entered clinical trials

  • Last Update: 2021-12-31
  • Source: Internet
  • Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationTom Lee

Previously, it was reported that ErSO, a small molecule drug from Bayer, has a 95% to 100% success rate for the treatment of cancer cells in animals

This therapy ErSO is a new drug developed by researchers at the University of Illinois in the United States.

In September 2020, Bayer signed an agreement to purchase the development license for the drug for US$370 million and cooperated with Arizona-based Systems Oncology to develop the drug

However, according to the latest reports, since the partnership between the two companies is no longer effective, the two companies' cooperation project on the tumor therapy has also reached a deadlock

Metastatic estrogen receptor-positive breast cancer is the most common type of breast cancer, and there is currently no cure.

ErSO Activism manager Danny Goss expressed his disappointment.

At the same time, Professor Shapiro and his team said they will continue to study ErSO therapy

Reference source:



This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Contact Us

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.